MEI Pharma Inc (NASDAQ:MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced updated results from a Phase II …
I stumbled upon MEI Pharma Inc (NASDAQ:MEIP) after reading over the American Society of Hematology (ASH) abstracts at the end of last year. …
The first quarter of 2015 has come to a close and companies are still releasing earnings reports. Let’s look back and see which …
MEI Pharma Inc (NASDAQ:MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced new pre-clinical data showing mitochondria-specific …
Written by Scott Matusow. Sometimes in biotech, things do not go as expected.
The investment firm Cantor Fitzgerald lowered its price target today on MEI Pharma Inc (NASDAQ:MEIP) to $7.00 (from $14.
MEI Pharma Inc (NASDAQ:MEIP) shares are down almost 70% today following the news that the company's cancer drug Pracinostat failed to meet the primary endpoint of a Phase …
Cantor’s healthcare analyst Daniel Brims weighed in today with an optimistic view on MEI Pharma Inc (NASDAQ:MEIP), after the company's cancer drug failed to meet the main goal …
Roth Capital’s healthcare analyst Joseph Pantginis weighed in with a few insights on MEI Pharma (NASDAQ:MEIP), after the company provided an update from its MEI-004 Phase II study …
Cowen analyst Boris Peaker reiterated an Outperform rating on MEI Pharma (NASDAQ:MEIP), as the company reported clinical activity from a Phase II study of …
